Breast Cancer. Measurability of Quality Performance Indicators Version 1.0: April 2012

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Breast Cancer. Measurability of Quality Performance Indicators Version 1.0: April 2012"

Transcription

1 Breast Cancer Measurability of Quality Performance Indicators Version 1.0: April 2012 (to be read in conjunction with the Breast Cancer Clinical Quality Performance Indicators Engagement Document v1.0 and the Breast Cancer Data Definitions v1.0) July

2 Quality Performance Indicators for Breast Cancer QPI 1 Non-Operative Diagnosis QPI Title: Patients with breast cancer should have a non-operative histological diagnosis. Description: Rationale and Evidence: Specifications: Proportion of patients with invasive or in-situ breast cancer who have a non-operative diagnosis (core biopsy / large volume biopsy). Diagnosis of patients non-operatively allows them to have only one definitive procedure, where possible. A lesion considered malignant should have histopathological confirmation of malignancy before any definitive surgical procedure takes place 4. Numerator: Number of patients with a non-operative diagnosis of breast cancer (core biopsy / large volume biopsy). ( Histological opinion (Breast Core Biopsy)coded as Malignant Not assessable or Malignant In-situ or Malignant invasive [NEEDBIO = B5 B5a B5b] Date of breast core biopsy before or on Date of first surgery [NBIODATE BSURGDATE] ) ( Histological opinion (Nodal Core Biopsy) coded as Malignant breast [NODEBIO = 5] Date of nodal core biopsy on or before Date of first surgery [NODEBIODATE BSURGDATE] ) Denominator: All patients with invasive or in-situ breast cancer. Date of Diagnosis [DIAGDATE] in range specified for comparative analysis Exclusions: All breast cancer patients with lobular carcinoma in situ (LCIS). Not recorded: Type of tumour coded as LCIS non-invasive [TUMOUR = 19] Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target 1) Denominator criteria coded as not recorded: July

3 Date of Diagnosis coded as Not recorded [DIAGDATE = 09/09/0909] 2) Exclusion criteria coded as not recorded (for patients already selected for inclusion in denominator only): Type of tumour coded as Not known [TUMOUR = 99] 3) Numerator criteria coded as not recorded (for patients who would otherwise be selected for inclusion in the numerator): Histological opinion (Breast Core Biopsy)coded as Not recorded [NEEDBIO = 99] Date of breast core biopsy coded as Not recorded [NBIODATE = 09/09/0909] Date of first surgery coded as Not recorded [BSURGDATE = 09/09/0909] Histological opinion (Nodal Core Biopsy) coded as Not recorded [NODEBIO = 99] Date of nodal core biopsy coded as Not recorded [NODEBIODATE = 09/09/0909] Target: 95% The tolerance within this target accounts for the fact that it may not always be technically possible to undertake a biopsy and factors of patient choice. July

4 QPI 2 Pre-Operative Assessment of Axilla QPI Title: Patients with breast cancer should have pre-operative assessment of the axilla. Description: Proportion of patients with invasive breast cancer who undergo assessment of the axilla: (i) ultrasound (ii) +/- FNA/core biopsy if suspicious morphology is reported on ultrasound, before surgery. Please note: This QPI measures 2 distinct elements: (i) All patients with invasive breast cancer should undergo ultrasound assessment of the axilla; and (ii) If findings of ultrasound are suspicious of cancer spread to nodes all patients should undergo FNA/core biopsy The specifications are therefore separated to ensure clear measurement of both these factors. Rationale and Evidence: A preoperative diagnosis of nodal disease enables definitive treatment of the axilla at the time of initial breast surgery 5. Patients with invasive breast cancer should undergo pre-treatment ultrasound assessment of the axilla. If morphologically suspicious nodes are identified these should be sampled, using FNA or core biopsy 5 6. Specifications (i): Numerator: Number of patients with invasive breast cancer who undergo assessment of the axilla by ultrasound before surgery. Ultrasound Examination of Axilla coded as Yes [ULTRAXIL = 1] Denominator: All patients with invasive breast cancer undergoing surgery. Date of Diagnosis [DIAGDATE] in range specified for comparative analysis Type of tumour coded as 'Ductal'/no specific type (NST) or Lobular carcinoma or Medullary carcinoma or Mucinous carcinoma or Tubular carcinoma or Mixed (invasive) or Other invasive [TUMOUR = ] Final Definitive Surgery coded as Mastectomy or Other or Axillary surgery alone or Mastectomy plus immediate reconstruction or Localising or excision biopsy or Conservation surgery [SURGBRST = ] Exclusions: No exclusions. Not recorded: Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target 1) Denominator criteria coded as not recorded, and where patient would otherwise be selected for inclusion in the denominator: July

5 Date of Diagnosis coded as Not recorded [DIAGDATE = 09/09/0909] Type of tumour coded as Not recorded [TUMOUR = 99] Final Definitive Surgery coded as Not known [SURGBRST = 99] 2) Exclusion criteria coded as not recorded (for patients already selected for inclusion in denominator only): ***No exclusions*** 4) Numerator criteria coded as not recorded (for patients who have been selected for inclusion in the denominator): Ultrasound Examination of Axilla coded as Not known [ULTRAXIL =99] Target: 95% The tolerance within this target accounts for the fact that some patients may refuse investigation and/or treatment. Specifications (ii): Numerator: Number of patients with invasive breast cancer with suspicious morphology reported on ultrasound who undergo a FNA/core biopsy of the axilla before surgery. ( Date Nodal Cytology of Axilla Performed [NODEDATE] Date Nodal Core Biopsy of Axilla Performed [AXILBIODATE] ) < (before) Date of First Definitive Breast Surgery [BSURGDATE] July

6 Denominator: All patients with invasive breast cancer undergoing surgery with suspicious morphology reported on ultrasound. Exclusions: No exclusions. Date of Diagnosis [DIAGDATE] in range specified for comparative analysis Type of tumour coded as 'Ductal'/no specific type (NST) or Lobular carcinoma or Medullary carcinoma or Mucinous carcinoma or Tubular carcinoma or Mixed (invasive) or Other invasive [TUMOUR = ] Final Definitive Surgery coded as Mastectomy or Other or Axillary surgery alone or Mastectomy plus immediate reconstruction or Localising or excision biopsy or Conservation surgery [SURGBRST = ] Ultrasound findings {Breast cancer} coded as Indeterminate or Suspicious or Malignant [ULTRA = U3 U4 U5] July

7 Not recorded: Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target 3) Denominator criteria coded as not recorded, and where patient would otherwise be selected for inclusion in the denominator: Date of Diagnosis coded as Not recorded [DIAGDATE = 09/09/0909] Type of tumour coded as Not recorded [TUMOUR = 99] Final Definitive Surgery coded as Not known [SURGBRST = 99] Ultrasound findings {Breast cancer} coded as Not known [ULTRA = 99] 4) Exclusion criteria coded as not recorded (for patients already selected for inclusion in denominator only): ***No exclusions*** 5) Numerator criteria coded as not recorded (for patients who would otherwise be selected for inclusion in the numerator): Date Nodal Cytology of Axilla Performed coded as Not known [NODEDATE=09/09/0909] Date Nodal Core Biopsy of Axilla Performed coded as Not known [AXILBIODATE =09/09/0909] Date of First Definitive Breast Surgery coded as Not known [BSURGDATE =09/09/0909] Target: 85 % The tolerance within this target accounts for the fact that FNA/core biopsy of the axilla it is not always technically possible. July

8 QPI 3 Conservation Rate QPI Title: Description: Rationale and Evidence: Patients with small breast cancers should undergo breast conservation whenever appropriate*. Proportion of surgically treated patients with breast cancer less than 20mm whole tumour size on histology who achieve breast conservation. Breast conservation is appropriate for small breast cancers. Randomised trials have shown no difference in survival for tumours treated by conservation surgery followed by radiotherapy to mastectomy 4. *Breast conservation may not be appropriate for all patients for a variety of reasons including patient choice, genetic risk and small breast size 7. Specifications: Numerator: Denominator: Number of surgically treated breast cancer patients with tumour less than 20mm whole tumour size on histology (invasive plus in situ disease) treated by breast conservation surgery. Final Definitive (or Only) Surgery Performed to Breast coded as Localising or excision biopsy or conservation surgery [SURGBRST = 11 12] All surgically treated patients with breast cancer with tumour less than 20mm whole tumour size on histology (invasive plus in situ disease). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis Final Definitive Surgery coded as Mastectomy or Other or Axillary surgery alone or Mastectomy plus immediate reconstruction or Localising or excision biopsy or Conservation surgery [SURGBRST = ] Maximum microscopic Whole Tumour Diameter less than 20mm [WHOLEDIAM < 20] July

9 Exclusions: All patients with multifocal breast cancer. All patients with breast cancer who have received neoadjuvant systemic therapy for 6 weeks (hormonal therapy or chemotherapy). Tumour extent coded as Multiple invasive foci or Multiple DCIS foci or Multiple foci includes Invasive & DCIS [EXTENT = 2 3 4] Type of hormone therapy coded as Neo-adjuvant [HMON = 2] ( Type of chemotherapy 1 coded as Neo-adjuvant [CHEM1 = 2] Date treatment completed (chemotherapy) 1 minus Date treatment started (chemotherapy) 1 greater than or equal to 6 weeks [CHEMENDATE1 CHEMDATE1 42 (days)] ) ( Type of chemotherapy 2 coded as Neo-adjuvant [CHEM2 = 2] Date treatment completed (chemotherapy) 1 minus Date treatment started (chemotherapy) 1 plus Date treatment completed (chemotherapy) 2 minus Date treatment started (chemotherapy) 2 greater than or equal to 6 weeks [(CHEMENDATE1 CHEMDATE1) + (CHEMENDATE2 CHEMDATE2) 42 (days)] ) Not recorded: Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target July ) Denominator criteria coded as not recorded, and where patient would otherwise be selected for inclusion in the denominator: Date of Diagnosis coded as not recorded [DIAGDATE = 09/09/0909] Final Definitive (or only) Surgery Performed to Breast coded as Not known [SURGBRST = 99]

10 Maximum microscopic Whole Tumour Diameter coded as Not recorded [WHOLEDIAM = 9999] 2) Exclusion criteria coded as not recorded (for patients who would otherwise be selected for inclusion in denominator): Tumour extent coded as Not known [EXTENT = 99] Type of hormone therapy coded as Not known [HMON = 99] Type of chemotherapy 1 coded as Not known [CHEM1 = 99] Date treatment completed (chemotherapy) 1 coded as Not recorded [CHEMENDATE1 = 09/09/0909] Date treatment started (chemotherapy) 1 coded as Not recorded [CHEMDATE1 = 09/09/0909] Type of chemotherapy 2 coded as Not known [CHEM2 = 99] Date treatment completed (chemotherapy) 2 coded as Not recorded [CHEMENDATE2 = 09/09/0909] Date treatment started (chemotherapy) 2 coded as Not recorded [CHEMDATE2 = 09/09/0909] Target: 85% The tolerance within this target accounts for the fact that breast conservation may not always be an appropriate treatment option for a variety of reasons, primarily patient choice. July

11 QPI 4 Surgical Margins QPI Title: Description: Breast cancers which are surgically treated should be adequately excised. Proportion of surgically treated patients with breast cancer (invasive or ductal carcinoma in situ) with final radial excision margins of less than 1mm. Rationale and Evidence: There is an increased risk of local recurrence if radial surgical excision margins is less than 1mm after breast cancer surgery 4. Numerator: Number of patients with breast cancer (invasive or ductal carcinoma in situ) having breast conservation surgery with final radial (i.e. superior, inferior, medial or lateral) excision margins less than 1mm (on pathology report). Distance from Final Radial Excision Margin coded as <1mm [DISTEX = 1 ] Denominator: All patients with breast (invasive or ductal carcinoma in situ) cancer having breast conservation surgery. Exclusions: LCIS alone Date of Diagnosis [DIAGDATE] in range specified for comparative analysis Final Definitive (or Only) Surgery Performed to Breast coded as Localising or excision biopsy or conservation surgery [SURGBRST = 11 12] Type of tumour coded as LCIS (non-invasive) [TUMOUR = 19] July

12 Not recorded: Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target 1) Denominator criteria coded as not recorded: Date of Diagnosis coded as Not recorded [DIAGDATE = 09/09/0909] Final Definitive (or Only) Surgery Performed to Breast coded as Not known [SURGBRST = 99] 2) Exclusion criteria coded as not recorded (for patients already selected for inclusion in denominator only): Type of tumour coded as Not known [TUMOUR = 99] 3) Numerator criteria coded as not recorded (for patients who would otherwise be selected for inclusion in the numerator only): Distance from Final Radial Excision Margin coded as Not recorded [DISTEX = 99] Target: <5% This QPI is measuring the proportion of patients who undergo surgery where the tumour has not been completely excised, a less than target level has therefore been set. July

13 QPI 5 Immediate Reconstruction Rate QPI Title: Patients undergoing mastectomy for breast cancer should have access to immediate breast reconstruction. Description: Rationale and Evidence: Proportion of patients who undergo immediate breast reconstruction at the time of mastectomy for breast cancer. Evidence suggests that breast reconstruction is not associated with an increase in the rate of local recurrence, nor does it affect the ability to detect recurrence, and it can yield psychological benefit. There may be good reasons for individual patients not to undergo immediate breast reconstruction but this indicator is intended to demonstrate that mastectomy patients have access to a reconstructive service 4 7. Access to immediate breast reconstruction is very difficult to measure accurately therefore uptake is utilised within this QPI as a proxy for access. Although it will not provide an absolute measure of patient access to this procedure it will give an indication of access across NHS Boards and highlight any areas of variance which can then be further examined. Specifications: Numerator: Denominator: Number of patients with breast cancer undergoing immediate breast reconstruction at the time of mastectomy. Final definitive (or only) surgery performed to breast coded as Mastectomy plus immediate reconstruction [SURGBRST = 7] All patients with breast cancer undergoing mastectomy. Date of Diagnosis [DIAGDATE] in range specified for comparative analysis Final Definitive (or Only) Surgery Performed to Breast coded as mastectomy or Mastectomy plus immediate reconstruction [SURGBRST = 4 7] Exclusions: All patients with M1 disease 1. TNM Metastasis Classification (pre-operative) {breast cancer} coded as Distant metastasis present [CM = M1] 1 The exclusion of patients with M1 disease is not intended to imply that mastectomy and immediate reconstruction is not a valid treatment option for patients with metastatic disease. The development group recommend that all patients are discussed on an individual basis to determine the most appropriate treatment. July

14 Not recorded: Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target 1) Denominator criteria coded as not recorded: Date of Diagnosis coded as Not recorded [DIAGDATE = 09/09/0909] Final Definitive (or Only) Surgery Performed to Breast coded as Not known [SURGBRST = 99] 2) Exclusion criteria coded as not recorded (for patients already selected for inclusion in denominator only): TNM Metastasis Classification (pre-operative) {breast cancer} coded as Not known [CM = 99] Target: >10% The tolerance within this target accounts for the fact that patient choice is a key factor in the number of patients who undergo immediate breast reconstruction at the time of mastectomy. July

15 QPI 6 Negative Axillary Clearance Rate QPI Title: Over treatment of the axilla should be minimised. Description: Rationale/ and Evidence: Proportion of patients with breast cancer undergoing axillary clearance with no pathological evidence of nodal metastatic disease*. Surgical axillary clearance is associated with increased arm morbidity compared with other surgical staging procedures and should therefore not be utilised unless there is evidence of nodal metastatic disease 4. Preoperative investigation of the axilla should minimise the need for surgical axillary clearance as a staging procedure 7. Specifications: Numerator: Denominator: Number of breast cancer patients undergoing surgical axillary clearance found to have no nodal metastasis* (including nodes taken at any previous sampling procedure). Total Number of Lymph Nodes Involved equals 0 : [INVNODES = 0] All patients with breast cancer undergoing surgical axillary clearance. Date of Diagnosis [DIAGDATE] in range specified for comparative analysis ( First Axillary Surgery coded as Clearance [FIRSTAXIL = 2] Final Axillary Surgery coded as Clearance [FINALAXIL = 2] ) July

16 Exclusions: All patients with breast cancer who have received neoadjuvant systemic therapy for 6 weeks (hormonal therapy or chemotherapy. Type of hormone therapy coded as Neo-adjuvant [HMON = 2] ( Type of chemotherapy 1 coded as Neo-adjuvant [CHEM1 = 2] Date treatment completed (chemotherapy) 1 minus Date treatment started (chemotherapy) 1 greater than or equal to 6 weeks [CHEMENDATE1 CHEMDATE1 42 (days)] ) ( Type of chemotherapy 2 coded as Neo-adjuvant [CHEM2 = 2] Date treatment completed (chemotherapy) 1 minus Date treatment started (chemotherapy) 1 plus Date treatment completed (chemotherapy) 2 minus Date treatment started (chemotherapy) 2 greater than or equal to 6 weeks [(CHEMENDATE1 CHEMDATE1) + (CHEMENDATE2 CHEMDATE2) 42 (days)] ) Not recorded: Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target July ) Denominator criteria coded as not recorded (where patients meet all other denominator criteria): Date of Diagnosis coded as Not recorded [DIAGDATE = 09/09/0909] ( First Axillary Surgery coded as Not known [FIRSTAXIL = 99] Final Axillary Surgery NOT coded as Clearance [FINALAXIL NOT 2] )

17 ( Final Axillary Surgery coded as Not known [FINALAXIL = 99] First Axillary Surgery NOT coded as Clearance [FIRSTAXIL NOT 2] ) 2) Exclusion criteria coded as not recorded (for patients who would otherwise be selected for inclusion in denominator only): Type of hormone therapy coded as Not known [HMON = 99] Type of chemotherapy 1 coded as Not known [CHEM1 = 99] Date treatment completed (chemotherapy) 1 coded as Not recorded [CHEMENDATE1 = 09/09/0909] Date treatment started (chemotherapy) 1 coded as Not recorded [CHEMDATE1 = 09/09/0909] Type of chemotherapy 2 coded as Not known [CHEM2 = 99] Date treatment completed (chemotherapy) 2 coded as Not recorded [CHEMENDATE2 = 09/09/0909] Date treatment started (chemotherapy) 2 coded as Not recorded [CHEMDATE2 = 09/09/0909] 3) Numerator criteria coded as not recorded (for patients already selected for inclusion in denominator only): Total Number of Lymph Nodes Involved coded as Not known or not recorded [INVNODES = 9999] Target: <10% This QPI is measuring the number of patients who undergo surgical axillary clearance who have no nodal metastases, i.e. patients who have over treatment of the axilla, therefore a less than target has been set. * see data item Total Number of Lymph Nodes Involved in the national minimum core dataset for full definition of nodal metastasis July

18 QPI 7: Minimising Hospital Stay - 23 Hour Surgery QPI Title: Patients should have the opportunity for 23 hour surgery (a maximum of 1 overnight stay following surgery) wherever appropriate. Description: Proportion of patients undergoing wide excision and/or an axillary sampling procedure for breast cancer with a maximum of 1 night hospital stay following their procedure. Rationale and Evidence: It is safe to perform wide excision and axillary staging as a short stay procedure in the majority of patients and clinical quality has been shown to be improved utilising this model, resulting in better patient outcomes. Benefits of short stay following surgery include: reduction in re-admissions, reduction in complications, improved patient mobility and enhanced recovery 8. Specifications: Numerator: Number of patients with breast cancer undergoing wide excision and/or axillary sampling procedure (sentinel node biopsy or node sample ( 4 nodes) with a maximum hospital stay of 1 night following their procedure. Denominator: All patients with breast cancer undergoing wide excision and/or axillary sampling procedure (sentinel node biopsy or node sample ( 4 nodes). Exclusions: All patients with breast cancer undergoing partial breast reconstruction. Target: 80% The tolerance within this target takes account of the fact that 23 hour surgery may not be appropriate for all patients due to social circumstances, co-morbidities and/or the geographical area in which they live. It may not always be safe or practical for patients to go home immediately after surgery; this may therefore affect short-stay surgery rates across NHS Scotland. Please note: SMR01 data will be utilised to support reporting and monitoring of this QPI rather than clinical audit. This will maximise the use of data which are already collected and remove the need for any duplication of data collection. Standard reports are currently being specified and direct access for each Board to run these reports is being investigated to ensure nationally consistent analysis and reporting. July

19 QPI 8 HER2 Status for Decision Making QPI Title: HER2 status should be available to inform treatment decision making. Description: Rationale and Evidence: Proportion of patients with invasive breast cancer for whom the HER2 status, as defined by ImmunoHistoChemistry (IHC), is known at the initial multidisciplinary team (MDT) meeting to decide first treatment. HER2 status has a significant impact on survival and so has a significant influence on decisions on neoadjuvant and adjuvant treatment 5. Delay in the availability of a HER2 result may lead to a delay in appropriate neoadjuvant or adjuvant therapy and make communication of a clear plan to the patient more difficult. Specifications: At present HER2 testing is undertaken in all relevant cases; however the point of the patient pathway at which this takes place varies across NHS Scotland. The purpose of this indicator is to synchronise practice across Scotland by ensuring the availability of HER2 status to inform treatment decision making. Numerator: Number of patients with invasive breast cancer for whom the HER2 status (as defined by IHC) is known at initial MDT meeting to decide first treatment. Human Epidermal Growth Factor Receptor-2 (HER2) Status Available at Initial MDT {Breast Cancer} coded as Yes [HER2AVAIL = 1] Denominator: All patients with invasive breast cancer. Date of Diagnosis [DIAGDATE] in range specified for comparative analysis Type of tumour coded as 'Ductal'/no specific type (NST) or Lobular carcinoma or Medullary carcinoma or Mucinous carcinoma or Tubular carcinoma or Mixed (invasive) or Other invasive [TUMOUR = ] Exclusions: No exclusions. Not recorded: Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target 1) Denominator criteria coded as not recorded: Date of Diagnosis coded as Not recorded [DIAGDATE = 09/09/0909] Type of tumour coded as Not known [TUMOUR = 99] 2) Exclusion criteria coded as not recorded (for patients already selected for inclusion in denominator July

20 only): ***No exclusions*** 3) Numerator criteria coded as not recorded (for patients already selected for inclusion in denominator only): Human Epidermal Growth Factor Receptor-2 (HER2) Status Available at Initial MDT {Breast Cancer} coded as Not known [HER2AVAIL = 99] Target: 90% The tolerance within this target accounts for the fact that it is not always possible to undertake IHC on a core biopsy, e.g. due to tumour size. July

21 QPI 9 Radiotherapy for Breast Conservation QPI Title: After wide local excision patients with breast cancer should receive radiotherapy. Description: Proportion of patients with breast cancer who receive radiotherapy to the breast after conservation for invasive cancer. Rationale and Evidence: Trials have demonstrated a significant reduction in local recurrence with the use of radiotherapy after breast conservation 9. Clinical trials of radiotherapy have shown it can produce a reduction in local recurrence would produce an absolute increase in 20-year survival of about 2-4% Specifications: Numerator: Denominator: Number of breast cancer patients with invasive breast cancer having conservation surgery receiving radiotherapy to the breast. Site of external beam radiotherapy coded as Breast [RADSITE1 or RADSITE 2 or RADSITE 3 or RADSITE 4 or RADSITE 5 = 1] All patients with invasive breast cancer having conservation surgery. Date of Diagnosis [DIAGDATE] in range specified for comparative analysis Type of Tumour coded as: [TUMOUR = 11 Or 12 Or 13 Or 14 Or 15 Or 16 Or 17] Final definitive (or only) surgery performed to breast coded as Localising or excision biopsy or conservation surgery [SURGBRST = 11 or 12] Exclusions: All patients with breast cancer taking part in clinical trials of radiotherapy treatment. All patients with M1 disease. Patient Entered into Clinical Trial coded as Yes, radiotherapy [TRIAL = 1A] TNM Metastases Classification (Pre-operative) coded as Distant metastases present [cm = M1] Not recorded: Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target 1) Denominator criteria coded as not recorded (for patients who otherwise meet all other denominator criteria): July

22 Date of Diagnosis coded as Not recorded [DIAGDATE = 09/09/0909] Type of Tumour coded as Not known [TUMOUR = 99] Final definitive (or only) surgery performed to breast coded as Not known [SURGBRST = 99] 2) Exclusion criteria coded as not recorded (for patients already selected for inclusion in denominator only): Patient Entered into Clinical Trial coded as Not known [TRIAL = 99] TNM Metastases Classification (Pre-operative) coded as Not known [cm = 99] 3) Numerator criteria coded as not recorded (for patients who would otherwise be selected for inclusion in the numerator only): Site of external beam radiotherapy coded as Not known [RADSITE1 or RADSITE 2 or RADSITE 3 or RADSITE 4 or RADSITE 5 = 99]* *only where all other Site of external beam radiotherapy sites [RADSITE1-5] are NOT coded as breast Target: 95% The tolerance within this target accounts for factors of patient choice and fitness for treatment. July

23 QPI 10 Adjuvant Chemotherapy QPI Title: Patients with higher risk breast cancer should receive chemotherapy post operatively. Description: Proportion of patients between 50 and 70 years of age at diagnosis with surgically proven node positive or at least G3 >20mm breast cancer who receive adjuvant chemotherapy. Rationale/ and Evidence: Large randomised trials have confirmed that adjuvant systemic therapy improves relapse-free survival and overall survival. 9 Clinical trials have demonstrated that adjuvant drug treatments substantially reduce 5-year recurrence rates and 15-year mortality rates 13. Treatment is not restricted by age and is considered on an individual patient basis. Treatment may be restricted by comorbidities, which are more common in the older patient group. Due to the difficulties associated with accurate measurement of co-morbidities and patient fitness these cannot be utilised as exclusions within this QPI. To ensure focussed measurement and a QPI examining expected outcomes the age range of years has been selected. This represents the majority of patients and therefore provides a good proxy for access to adjuvant chemotherapy in the whole patient population. Patients over 70 years of age have been poorly represented in previous clinical trials meaning that the evidence base for benefit in the over 70 age group is extremely limited. This does not affect clinical practice, as patients are considered for treatment on an individual basis. Specifications: Numerator: Number of patients between 50 and 70 years of age at diagnosis with surgically proven node positive or at least G3 >20mm breast cancer who receive adjuvant chemotherapy. Type of Chemotherapy 1-2 coded as Adjuvant [CHEM1 CHEM2 = 1] July

24 Denominator: All patients between 50 and 70 years of age at diagnosis with surgically proven node positive or at least G3 >20mm breast cancer. Date of Diagnosis [DIAGDATE] (minus) Date of birth [DOB] > (greater than) 50 years and < (less than) 70 years ( Total Number of Lymph Nodes Involved not coded as inapplicable [INVNODES >0 NOT 1010] ( Tumour Grade coded as Grade III [TGRADE = 3] Maximum Microscopic Whole Tumour Diameter {Cancer} greater than 20mm and not not assessable or inapplicable [WHOLEDIAM > 20 NOT ( )] ) ) Exclusions: All patients with breast cancer taking part in trials of chemotherapy treatment. All patients with breast cancer who have had neo-adjuvant chemotherapy All patients with M1 disease. Not recorded: Patient entered into Clinical Trial coded as Chemotherapy [TRIAL = 1B] Type of Chemotherapy 1-2 coded as Neoadjuvant [CHEM1 CHEM2 = 2] TNM Metastases Classification (Pre-operative) coded as Distant metastases present [cm = M1] Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target July ) Denominator criteria coded as not recorded (where all other denominator criteria has been met): Date of Diagnosis coded as Not recorded [DIAGDATE = 09/09/0909] Date of birth coded as Not recorded [DOB = 09/09/0909] Total Number of Lymph Nodes Involved coded as not recorded [INVNODES = 9999] Tumour Grade coded as Not known [TGRADE = 99] Maximum Microscopic Whole Tumour Diameter {Cancer} coded as Not recorded [WHOLEDIAM = 9999]

25 2) Exclusion criteria coded as not recorded (for patients already selected for inclusion in denominator only): Patient entered into Clinical Trial coded as Not known [TRIAL = 99] Type of Chemotherapy 1-2 coded as Not known [CHEM1 CHEM2 = 99] TNM Metastases Classification (Pre-operative) coded as Not known [M = 99] 3) Numerator criteria coded as not recorded (for patients already selected for inclusion in denominator only): Type of Chemotherapy 1-2 coded as Not known [CHEM1 CHEM2 = 99] Target: 85% The tolerance within this target accounts for factors of patient choice, co-morbidities and fitness for treatment. July

26 QPI 11 Anti-HER2 Positive Therapy QPI Title: Patients with HER2 positive intermediate or high risk breast cancer should receive anti-her2 positive therapy. Description: Rationale/ and Evidence: Proportion of patients with breast cancer (who are between 50 and 70 years of age at diagnosis) with HER2 positive cancer greater than 10 mm or node-positive who receive anti-her2 positive therapy. Women with intermediate or high risk-disease who are HER2 positive show benefit when they receive trastuzumab in addition to chemotherapy 9. Clinical trails have shown a highly significant increase in 3yr disease-free survival with the use of adjuvant trastuzumab Treatment is not restricted by age and is considered on an individual patient basis. Treatment may be restricted by comorbidities, which are more common in the older patient group. Due to the difficulties associated with accurate measurement of co-morbidities and patient fitness these cannot be utilised as exclusions within this QPI. To ensure focussed measurement and a practically useful QPI the age range of years has been selected as the population of measurement, this represents the majority of patients and therefore provides a good proxy for patient s receiving adjuvant chemotherapy in the whole patient population. Patients over 70 years of age have been poorly represented in previous clinical trials meaning that the evidence base for benefit in the over 70 age group is extremely limited. This does not affect clinical practice, as patients are considered for treatment on an individual basis. Specifications: Numerator: Number of patients with breast cancer who are between 50 and 70 years of age at diagnosis with HER2 positive (by 3+ on IHC &/or FISH +ve) tumours >10mm (or 10mm and node positive) who receive adjuvant anti-her2 positive therapy. Biological agent coded as Anti-HER2 positive therapy [BIOAGENT = 1] Date Treatment Started {Cancer} (Biological Therapy) after Date of first treatment [BIODATE > FIRSTTREATDATE] July

27 Denominator: All patients with breast cancer who are between 50 and 70 years of age at diagnosis with HER2 positive (by 3+ on IHC &/or FISH +ve). tumours >10mm (or 10mm and node positive). Date of Diagnosis minus Date of birth greater than 50 years and less than 70 years [DIAGDATE DOB > 50 years < 70 years] EITHER ( Human Epidermal Growth Factor Receptor-2 Status coded as Positive [HER2STATUS = 1] Maximum Invasive Pathological Diameter greater than 10 [MAXPATH > 10] ) ( Human Epidermal Growth Factor Receptor-2 Status coded as Positive [HER2STATUS = 1] Maximum Invasive Pathological Diameter less than or equal to 10 [MAXPATH 10] Number of Lymph Nodes Involved not coded as Inapplicable [INVNODES > 0 NOT 1010] ) Exclusions: Not recorded: No exclusions. Patients with any aspect of their numerator, denominator or exclusion criteria coded as not recorded should be entered into the separate not recorded category and included in the denominator for measurement against the target July ) Denominator criteria coded as not recorded (where all other denominator criteria are met): Date of Diagnosis coded as Not known [DIAGDATE = 09/09/0909] Date of birth coded as Not known [DOB = 09/09/0909] Human Epidermal Growth Factor Receptor-2 Status coded as Not known [HER2STATUS = 99] Maximum Invasive Pathological Diameter coded as Not known [MAXPATH = 99] Number of Lymph Nodes Involved coded as Not recorded [INVNODES = 9999]

28 2) Exclusion criteria coded as not recorded (for patients already selected for inclusion in denominator only): ***No exclusions*** 3) Numerator criteria coded as not recorded (where all other numerator criteria are met): Biological agent coded as Not known [BIOAGENT = 99] Date Treatment Started {Cancer} (Biological Therapy)coded as Not recorded [BIODATE = 09/09/0909] Date of first treatment coded as Not recorded [FIRSTTREATDATE = 09/09/0909] Target: 90% The tolerance within this target accounts for factors of patient choice, co-morbidities and fitness for treatment. July

29 References 1. Scottish Government (2008) Better Cancer Care: An Action Plan 2. Scottish Government (2010) NHS Scotland Healthcare Quality Strategy 3. Institute Of Medicine (2001) Crossing the Quality Chasm: A New Health System for the 21 st Century National Academy Press: Washington, DC. 4. Scottish Intercollegiate Guidelines Network. Management of breast cancer in women. Edinburgh: SIGN; SIGN Publication No NICE (2009) Breast Cancer (Early and Locally Advanced) Diagnosis and Treatment. Cardiff: NICE; February CG80 6. Willett et al (2010) Best Practice Diagnostic Guidelines for Patients Presenting with Breast Symptoms 7. NHS BSP (2009) Quality Assurance Guidelines for Surgeons in Breast Cancer Screening. Sheffield: NHS Cancer screening Programmes; Publication 20 Fourth Edition 8. NHS Improvement (2010) Ambulatory breast surgical care: day case/23-hour breast care 9. NHS Quality Improvement Scotland (2008) Management of breast cancer services Abe et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366 (9503): Fisher et al (2002) Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumour recurrence after lumpectomy in women with invasive breast cancers of one centimetre or less. Journal of Clinical Oncology 20 (20): Veronesi et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.new England Journal of Medicine 347 (16): Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365 (9472): Romond et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 353 (16): Piccart-Gebhart et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine 353 (16): Sant M, Aareleid T, Berrino F, Bielska LasotaM, Carli PM, FaivreJ, et al. (2003) EUROCARE-3: survival of breast cancer patients diagnosed results and commentary. Ann Oncol. 2003;14(Suppl 5):v61-v Thomson CS, Brewster DH, Dewar JA, Twelves CJ. (2004) Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment. Eur J Cancer. 2004;40(5): July

Breast Cancer. Measurability of Quality Performance Indicators Version 1.3

Breast Cancer. Measurability of Quality Performance Indicators Version 1.3 Breast Cancer Measurability of Quality Permance Indicators Version 1.3 To be read in conjunction with: Breast Cancer Quality Permance Indicators Breast Cancer Data Definitions v1.0 Breast Cancer QPI Measurability

More information

Breast Cancer Clinical Quality Performance Indicators

Breast Cancer Clinical Quality Performance Indicators Scottish Cancer Taskforce Breast Cancer Clinical Quality Performance Indicators March 2012 Published by: Scottish Government and Healthcare Improvement Scotland Contents Page 1. National Cancer Quality

More information

Understanding your pathology report

Understanding your pathology report Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What

More information

Surgical guidelines for the management of breast cancer

Surgical guidelines for the management of breast cancer Available online at www.sciencedirect.com EJSO xx (2009) S1eS22 www.ejso.com Guidelines Surgical guidelines for the management of breast cancer Contents Association of Breast Surgery at BASO 2009 Introduction...

More information

DOMINICAN HOSPITAL QUALITY IMPROVEMENT STUDY BREAST CANCER CARE

DOMINICAN HOSPITAL QUALITY IMPROVEMENT STUDY BREAST CANCER CARE DOMINICAN HOSPITAL QUALITY IMPROVEMENT STUDY BREAST CANCER CARE STUDY COORDINATOR: Jimmy Chung, MD 234 Surgical breast cancer patients admitted 2004-2008 Updated: 10/7/10 INTRODUCTION Breast cancer is

More information

SUMMARY. Sentinel Lymph Node Biopsy in Breast Cancer Treatment : Indications and Contraindications. Summary of the report prepared by Cathy Gosselin

SUMMARY. Sentinel Lymph Node Biopsy in Breast Cancer Treatment : Indications and Contraindications. Summary of the report prepared by Cathy Gosselin SUMMARY Sentinel Lymph Node Biopsy in Breast Cancer Treatment : Indications and Contraindications March 2012 A production of the Institut national d excellence en santé et en services sociaux Summary of

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

Updates in Breast Cancer: Radiation. Shirnett Matthews, MD Radiation Oncology Cancer Centers of the Carolinas

Updates in Breast Cancer: Radiation. Shirnett Matthews, MD Radiation Oncology Cancer Centers of the Carolinas Updates in Breast Cancer: Radiation Shirnett Matthews, MD Radiation Oncology Cancer Centers of the Carolinas Hughes et al. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 years of Age

More information

The best treatment Your guide to breast cancer treatment in England and Wales

The best treatment Your guide to breast cancer treatment in England and Wales The best treatment Your guide to breast cancer treatment in England and Wales If you are looking for information on the treatment of secondary breast cancer (also known as advanced or metastatic breast

More information

Invasive ductal breast cancer (IDC) Invasive breast cancer of no special type (NST) Breast cancer not otherwise specified (NOS)

Invasive ductal breast cancer (IDC) Invasive breast cancer of no special type (NST) Breast cancer not otherwise specified (NOS) Invasive ductal breast cancer (IDC) Invasive breast cancer of no special type (NST) Breast cancer not otherwise specified (NOS) This booklet describes what invasive ductal breast cancer is, the symptoms,

More information

Renal Cancer. Measurability of Quality Performance Indicators Version 1.1

Renal Cancer. Measurability of Quality Performance Indicators Version 1.1 Renal Cancer Measurability of Quality Permance Indicators Version 1.1 To be read in conjunction with: Renal Cancer Clinical Quality Permance Indicators Engagement Document v1.0 Renal Cancer Data Definitions

More information

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER Definitions: NACT is recommended initial treatment for inflammatory breast cancer and inoperable

More information

BREAST CANCER WHAT ARE MY SURGICAL OPTIONS?

BREAST CANCER WHAT ARE MY SURGICAL OPTIONS? BREAST CANCER WHAT ARE MY SURGICAL OPTIONS? Contents: The aims of surgery Know your surgical options Breast reconstruction Questions to ask your surgeon The aims of surgery Every woman is different and

More information

BREAST CANCER WHAT DO MY BIOPSY RESULTS MEAN?

BREAST CANCER WHAT DO MY BIOPSY RESULTS MEAN? BREAST CANCER WHAT DO MY BIOPSY RESULTS MEAN? Contents: The type of breast cancer The grade of the tumour Hormone receptor status HER2 status Questions to ask your doctor A biopsy is a procedure which

More information

2. Radiotherapy. "Practice Guidelines for Breast Cancer" Research. Questions. NCCN/JCCNB Seminar in Japan 2007 January January 26-27

2. Radiotherapy. Practice Guidelines for Breast Cancer Research. Questions. NCCN/JCCNB Seminar in Japan 2007 January January 26-27 NCCN/JCCNB Seminar in Japan 2007 January 13-14 2008 January 26-27 "Practice Guidelines for Breast Cancer" A Comparison between and Japan (: as of 2007, Japan: according to "Practice Guideline for Breast

More information

The best treatment Your guide to breast cancer treatment in Scotland

The best treatment Your guide to breast cancer treatment in Scotland The best treatment Your guide to breast cancer treatment in Scotland If you are looking for information on secondary breast cancer treatment, please see Breast Cancer Now s website: breastcancernow.org/

More information

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable

More information

Tubular breast cancer

Tubular breast cancer Tubular breast cancer This booklet is for people who would like more information about tubular breast cancer. It describes what tubular breast cancer is, its symptoms, how a diagnosis is made and the possible

More information

Guidelines for the treatment of breast cancer with radiotherapy

Guidelines for the treatment of breast cancer with radiotherapy London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal

More information

This vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years

This vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years Breast Cancer 2015 Annex C Background 1. Breast cancer is the most common cancer in women in England with (not including cases of ductal carcinoma in situ (DCIS) 1 ) 39,681 new cases diagnosed in 2008

More information

Types of treatment for breast cancer

Types of treatment for breast cancer Types of treatment for breast cancer Useful information for cancer patients Contents This information is about the main treatments used to treat breast cancer. There are sections on The main treatments

More information

Bradley W. Schenck, copyright ACHIEVING EXCELLENCE IN ABSTRACTING BREAST CANCER

Bradley W. Schenck, copyright ACHIEVING EXCELLENCE IN ABSTRACTING BREAST CANCER Bradley W. Schenck, copyright ACHIEVING EXCELLENCE IN ABSTRACTING BREAST CANCER ACHIEVING EXCELLENCE IN ABSTRACTING BREAST CANCER Recoding Audit Performed in 2009 260 cases audited 17 data items audited

More information

Detailed Pathology Methods for Using Residual Cancer Burden

Detailed Pathology Methods for Using Residual Cancer Burden Detailed Pathology Methods for Using Residual Cancer Burden Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after

More information

Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options

Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options Guideline 17-10 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications

More information

Breast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT. Five-year report

Breast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT. Five-year report Breast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT Five-year report Community Health Pathology Southern Area Health Service ACT Health General Practitioners Nurses Social

More information

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof

More information

Understanding Your Surgical Options For Breast Cancer

Understanding Your Surgical Options For Breast Cancer RADIATION THERAPY SYMPTOM MANAGEMENT CANCER INFORMATION Understanding Your Surgical Options For Breast Cancer In this booklet you will learn about: Role of surgery in breast cancer diagnosis and treatment

More information

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including

More information

Surgical Margins and follow up of Squamous Cell Carcinoma. Steve Keohane

Surgical Margins and follow up of Squamous Cell Carcinoma. Steve Keohane Surgical Margins and follow up of Squamous Cell Carcinoma Steve Keohane Poor registration Well established projected increase in incidence for next 2 decades Significant morbidity but relatively low mortality

More information

Invasive lobular breast cancer

Invasive lobular breast cancer Invasive lobular breast cancer This booklet is about invasive lobular breast cancer. It describes what invasive lobular breast cancer is, the symptoms, how it s diagnosed and possible treatments. Diagnosed

More information

Recommendations for cross-sectional imaging in cancer management, Second edition

Recommendations for cross-sectional imaging in cancer management, Second edition www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who

More information

Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics

Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics Edoardo Colzani, M.D., M.P.H. Department of Medical Epidemiology and Biostatistics

More information

Understanding ductal carcinoma in situ (DCIS) and deciding about treatment

Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Overview of Breast Cancer. Donna Graham Medical Oncology SpR

Overview of Breast Cancer. Donna Graham Medical Oncology SpR Overview of Breast Cancer Donna Graham Medical Oncology SpR Learning Points Epidemiology Risk Factors Diagnosis Prognostic Markers Stage 0 III disease Stage IV disease Surveillance Incidence in Ireland

More information

Ductal Carcinoma in Situ (DCIS)

Ductal Carcinoma in Situ (DCIS) Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Ductal Carcinoma in Situ (DCIS) Ductal Carcinoma in Situ DCIS Version 2002: Gerber Version 2003 2009: Audretsch / Brunnert

More information

Brain and CNS Cancer. Measurability of Quality Performance Indicators Version 2.3

Brain and CNS Cancer. Measurability of Quality Performance Indicators Version 2.3 Brain and CNS Cancer Measurability of Quality Permance Indicators Version 2.3 To be read in conjunction with: Brain and Central Nervous System Cancer Clinical Quality Permance Indicators Brain and Central

More information

Patient Guide to Early-Stage Invasive Breast Cancer Surgery and Treatment

Patient Guide to Early-Stage Invasive Breast Cancer Surgery and Treatment Patient Guide to Early-Stage Invasive Breast Cancer Surgery and Treatment Deborah C. Animal rehabilitation specialist and avid athlete. Diagnosed with invasive breast cancer in 2007. An educational guide

More information

Appendix One. HER2-positive early breast cancer, its treatment and prognosis

Appendix One. HER2-positive early breast cancer, its treatment and prognosis Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf

More information

See MP/H rules on the slides if you do not have your manual.

See MP/H rules on the slides if you do not have your manual. Quiz 1 1. Which of the following statements about the incidence of melanoma in the US over the last 30 years is true? a. Melanoma incidences have been going down for both men and women. b. Melanoma incidences

More information

ductal carcinoma in situ (DCIS)

ductal carcinoma in situ (DCIS) Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre

More information

Breast Cancer. CSC Cancer Experience Registry Member, breast cancer

Breast Cancer. CSC Cancer Experience Registry Member, breast cancer ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.

More information

TRAINING LOGBOOK. for ADVANCED SPECIALIST DIPLOMA HISTOLOGICAL DISSECTION BREAST PATHOLOGY ISSUED TO:

TRAINING LOGBOOK. for ADVANCED SPECIALIST DIPLOMA HISTOLOGICAL DISSECTION BREAST PATHOLOGY ISSUED TO: TRAINING LOGBOOK for ADVANCED SPECIALIST DIPLOMA in HISTOLOGICAL DISSECTION BREAST PATHOLOGY ISSUED TO: ASD HD Breast Pathology training logbook version 2.0 March 2014 Page 1 of 18 This document and its

More information

Chapter 2 Staging of Breast Cancer

Chapter 2 Staging of Breast Cancer Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination

More information

Guidelines for Management of Renal Cancer

Guidelines for Management of Renal Cancer Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated

More information

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

AJCC TNM and Summary Stage 10/2/14

AJCC TNM and Summary Stage 10/2/14 STAGE DATA: USING THE AJCC CANCER STAGING MANUAL 7 TH ED. AND SUMMARY STAGE 2000 Jim Hofferkamp, CTR (jhofferkam@naaccr.org) Shannon Vann, CTR (svann@naaccr.org) Q&A Please submit all questions concerning

More information

Based on SIOG recommendations: Lancet Oncol 2007 (8) p 1101

Based on SIOG recommendations: Lancet Oncol 2007 (8) p 1101 Breast cancer in the older pts H. Wildiers University Hospitals Leuven Belgium Based on SIOG recommendations: Lancet Oncol 2007 (8) p 1101 Introduction INCIDENCE: >40% occurs > 65y of age TUMOR BIOLOGY:

More information

A guide for women who are considering breast cancer treatment with chemotherapy and/or hormonal therapy before surgery

A guide for women who are considering breast cancer treatment with chemotherapy and/or hormonal therapy before surgery A guide for women who are considering breast cancer treatment with chemotherapy and/or hormonal therapy before surgery Contents Introduction... 1 What type of breast cancer do I have?... 2 What treatments

More information

Ductal carcinoma in situ (DCIS)

Ductal carcinoma in situ (DCIS) Ductal carcinoma in situ (DCIS) This booklet is for people who would like more information about ductal carcinoma in situ (DCIS). It describes what DCIS is, the possible symptoms, how it is diagnosed and

More information

Ductal carcinoma in situ (DCIS)

Ductal carcinoma in situ (DCIS) DIAGNOSIS: DCIS Ductal carcinoma in situ (DCIS) This factsheet gives information on an early form of breast cancer called ductal carcinoma in situ (DCIS). It explains what it is, how your breast is made

More information

Current Status and Perspectives of Radiation Therapy for Breast Cancer

Current Status and Perspectives of Radiation Therapy for Breast Cancer Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic

More information

TNM Staging Fact Sheet

TNM Staging Fact Sheet TNM Staging Fact Sheet Jan 2010 This document provides answers to some of the frequently asked questions posed by physicians, health information management professionals, and cancer program administrators,

More information

Northampton General Hospital. Breast Multi-Disciplinary Team. Management and Clinical Guidelines

Northampton General Hospital. Breast Multi-Disciplinary Team. Management and Clinical Guidelines Northampton General Hospital Breast Multi-Disciplinary Team Management and Clinical Guidelines The management of breast cancer will be the same regardless of whether the diagnosis is made is a screening

More information

Melanoma Quality Performance Indicators

Melanoma Quality Performance Indicators Publication Report Melanoma Quality Performance Indicators Patients diagnosed during July 2014 to June 2015 Publication date 17 May 2016 An Official Statistics Publication for Scotland Contents Introduction...

More information

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women

More information

Annual Report 2015 of the Certified Breast Cancer Centres (BCCs)

Annual Report 2015 of the Certified Breast Cancer Centres (BCCs) Annual Report 2015 of the Certified Breast Cancer Centres (BCCs) Audit year 2014 / indicator year 2013 Content Introduction Status of the certification system: Breast Cancer Centres 2015 General information

More information

Targeted therapies for Early Stage Breast Cancer. Cynthia Vakhariya D.O. Providence Hospital

Targeted therapies for Early Stage Breast Cancer. Cynthia Vakhariya D.O. Providence Hospital Targeted therapies for Early Stage Breast Cancer Cynthia Vakhariya D.O. Providence Hospital Case 55-year-old postmenopausal woman Routine screening mammogram 3 cm irreg mass in L breast Left breast ultrasound

More information

Edinburgh Breast Unit

Edinburgh Breast Unit Edinburgh Breast Unit Treatment: Questions and Answers about Breast Cancer in South East Scotland* These questions and answers will provide an overview of the standard approaches for treating breast cancer

More information

Breast Cancer Management Clinical Guidelines. Prepared by the Clinical Guidelines Committee Royal College of Surgeons in Ireland November 2000

Breast Cancer Management Clinical Guidelines. Prepared by the Clinical Guidelines Committee Royal College of Surgeons in Ireland November 2000 Breast Cancer Management Clinical Guidelines Prepared by the Clinical Guidelines Committee Royal College of Surgeons in Ireland November 2000 Mr. T. N. Walsh Prof. N. O Higgins Mr. T. N. Walsh Senior Lecturer

More information

Endometrial Cancer. Measurability of Quality Performance Indicators Version 2.0

Endometrial Cancer. Measurability of Quality Performance Indicators Version 2.0 Endometrial Cancer Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Endometrial Cancer QPIs Final Publication v2 Endometrial QPI Dataset (latest published version)

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES SARCOMA SOFT TISSUE SARCOMA Site Group: Sarcoma Soft Tissue Sarcoma Author: Dr. Peter Ferguson 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING

More information

Corporate Medical Policy Brachytherapy Treatment of Breast Cancer

Corporate Medical Policy Brachytherapy Treatment of Breast Cancer Corporate Medical Policy Brachytherapy Treatment of Breast Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_treatment_of_breast_cancer 7/1996 5/2015 5/2016 5/2015

More information

Guide to Understanding Breast Cancer

Guide to Understanding Breast Cancer An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients

More information

X-Plain Breast Cancer Reference Summary

X-Plain Breast Cancer Reference Summary X-Plain Breast Cancer Reference Summary The risk of breast cancer among Asian Americans living in the U.S. is relatively low compared to caucasian women. However, there is concern that the risk of breast

More information

Hereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center

Hereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center Hereditary Multifocal Breast Cancer Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center CASE STUDY 30 year old Ashkenazi Jewish woman Nulliparous Felt

More information

Focussing on Inequalities: Variation in breast cancer outcomes with age and deprivation

Focussing on Inequalities: Variation in breast cancer outcomes with age and deprivation Focussing on Inequalities: Variation in breast cancer outcomes with age and deprivation West Midlands Cancer Intelligence Unit ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS Acknowledgements ACKNOWLEDGEMENTS The authors

More information

Breast Cancer Treatment Guidelines

Breast Cancer Treatment Guidelines Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision

More information

Guideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer

Guideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer Guideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer Version History Version Date Summary of Change/Process 0.1 09.01.11

More information

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D. Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are

More information

Ductal Carcinoma in Situ (DCIS)

Ductal Carcinoma in Situ (DCIS) Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Ductal Carcinoma in Situ (DCIS) Ductal Carcinoma in Situ DCIS Version 2002: Gerber Versions 2003 2012: Audretsch / Brunnert

More information

Treating primary breast cancer

Treating primary breast cancer Treating primary breast cancer This booklet describes the treatments you may be offered if you have been diagnosed with primary (early) breast cancer. This information is by Breast Cancer Care. We are

More information

Phyllodes tumours: borderline malignant and malignant

Phyllodes tumours: borderline malignant and malignant Phyllodes tumours: borderline malignant and malignant This booklet is for people who would like more information on borderline malignant or malignant phyllodes tumours. It describes what they are, the

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

Triple Negative Breast Cancer, 2014: Expert Perspectives

Triple Negative Breast Cancer, 2014: Expert Perspectives Triple Negative Breast Cancer, 2014: Expert Perspectives A Guide for Patients This guide is based on an expert panel discussion titled "Triple Negative Breast Cancer: Practical Treatment Strategies," developed

More information

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

More information

Audit. Process for managing outliers in breast cancer surgery. March 2005

Audit. Process for managing outliers in breast cancer surgery. March 2005 Process for managing outliers in breast cancer surgery Audit March 2005 Prepared by: Australian Safety & Efficacy Register of New Interventional Procedures Surgical On behalf of: The Section of Breast

More information

Breast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.

Breast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor. Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast

More information

Breast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer.

Breast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Breast Cancer What Does the Pathology Report Say Normal Cells The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Non-Invasive

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

These guidelines have been withdrawn

These guidelines have been withdrawn These guidelines have been withdrawn MOH clinical practice guidelines are considered withdrawn five years after publication unless otherwise specified in individual guidelines. Users should keep in mind

More information

Patient Guide to Breast Cancer Surgery and Treatment

Patient Guide to Breast Cancer Surgery and Treatment Patient Guide to Breast Cancer Surgery and Treatment Coree H. Flight attendant and mother of 3. Diagnosed with invasive breast cancer in 2009. An educational guide prepared by Genomic Health This Is Your

More information

BREAST CANCER PATHOLOGY

BREAST CANCER PATHOLOGY BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know

More information

surgery choices For Women with Early-Stage Breast Cancer family EDUCATION PATIENT

surgery choices For Women with Early-Stage Breast Cancer family EDUCATION PATIENT surgery choices For Women with Early-Stage Breast Cancer PATIENT & family EDUCATION U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute NATIONAL RESEARCH

More information

Breast cancer is the most common cause of death from cancer in women in the UK. Effective interventions exist:

Breast cancer is the most common cause of death from cancer in women in the UK. Effective interventions exist: 6 Breast Cancer P Dey, E Twelves, CBJ Woodman 1 Summary Breast cancer is the most common cause of death from cancer in women in the UK. Effective interventions exist: population-based breast cancer screening

More information

Breast Cancer. Mary Yamashita, M.D. Assistant Professor of Radiology Breast Imaging University of Southern California Keck School of Medicine

Breast Cancer. Mary Yamashita, M.D. Assistant Professor of Radiology Breast Imaging University of Southern California Keck School of Medicine Breast Cancer Mary Yamashita, M.D. Assistant Professor of Radiology Breast Imaging University of Southern California Keck School of Medicine DISCLOSURE Neither I nor my spouse has any relevant financial

More information

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011 Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer Shannon Acker April 4, 2011 Rectal Cancer 40,870 new cases in the US in 2009 49,920 deaths from colorectal cancer Second leading cause

More information

Articles. Early Breast Cancer Trialists Collaborative Group (EBCTCG)* www.thelancet.com Vol 366 December 17/24/31, 2005 2087

Articles. Early Breast Cancer Trialists Collaborative Group (EBCTCG)* www.thelancet.com Vol 366 December 17/24/31, 2005 2087 Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists

More information

TNM staging and prognosis. Alexandru Eniu, MD, PhD Medical Oncologist Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca, Romania

TNM staging and prognosis. Alexandru Eniu, MD, PhD Medical Oncologist Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca, Romania TNM staging and prognosis Alexandru Eniu, MD, PhD Medical Oncologist Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca, Romania The Basics of TNM Staging Premises: Cancers of the same

More information

Prognosis of survival for breast cancer patients

Prognosis of survival for breast cancer patients Prognosis of survival for breast cancer patients Ken Ryder Breast Cancer Unit Data Section Guy s Hospital Patrick Royston, MRC Clinical Trials Unit London Outline Introduce the data and outcomes requested

More information

Evaluation and Management of the Breast Mass. Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003

Evaluation and Management of the Breast Mass. Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003 Evaluation and Management of the Breast Mass Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003 Common Presentations of Breast Disease Breast Mass Abnormal

More information

Data Definitions for the National Minimum Core Data Set to support the introduction of Testicular Cancer Quality Performance Indicators

Data Definitions for the National Minimum Core Data Set to support the introduction of Testicular Cancer Quality Performance Indicators Testicular Cancer Data Definitions for the National Minimum Core Data Set to support the introduction of Testicular Cancer Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration

More information

Breast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer.

Breast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Breast Cancer What Does the Pathology Report Say Normal Cells The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Non-Invasive

More information

Breast Cancer & Pregnancy. Heather R. Wright, M.D. University of Kentucky Department of Surgery

Breast Cancer & Pregnancy. Heather R. Wright, M.D. University of Kentucky Department of Surgery Breast Cancer & Pregnancy Heather R. Wright, M.D. University of Kentucky Department of Surgery Definitions Breast cancer during pregnancy vs. Pregnancy-associated breast carcinoma Breast carcinoma that

More information

National Breast and Ovarian Cancer Centre and Royal Australasian College of Surgeons

National Breast and Ovarian Cancer Centre and Royal Australasian College of Surgeons National Breast and Ovarian Cancer Centre and Royal Australasian College of Surgeons National Breast Cancer Audit Public Health Monitoring Series 2008 Data Published August 2010 National Breast and Ovarian

More information

SBI/ACR Breast Imaging Symposium April 7-10, 2016 Austin, TX

SBI/ACR Breast Imaging Symposium April 7-10, 2016 Austin, TX SBI/ACR Breast Imaging Symposium April 7-10, 2016 Austin, TX SAM Session 2 Friday, April 8 2.5 SAM Credits Thank you for completing this SAM activity. Below you will find correct responses, rationales,

More information

Allegheny Health Network. Breast Care Center

Allegheny Health Network. Breast Care Center Allegheny Health Network Breast Care Center Breast health is a top priority of every woman. At Allegheny Health Network, you ll find a full array of breast care services designed with your needs in mind.

More information

Understanding Your Breast Cancer Pathology Report *

Understanding Your Breast Cancer Pathology Report * Understanding Your Breast Cancer Pathology Report * * Note: Your pathology report may contain all or some of the sections covered in this guide. Remember, your healthcare team is always available to help

More information

Breast Cancer Treatment

Breast Cancer Treatment Scan for mobile link. Breast Cancer Treatment Breast cancer overview The American Cancer Society estimates that nearly 250,000 new cases of invasive breast cancer may be diagnosed in 2016. It is now possible

More information